EZB Stock Overview
A life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Enzo Biochem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$1.17 |
| 52 Week Low | US$0.37 |
| Beta | 0.77 |
| 1 Month Change | -21.86% |
| 3 Month Change | -60.21% |
| 1 Year Change | -66.14% |
| 3 Year Change | -86.21% |
| 5 Year Change | -82.61% |
| Change since IPO | -99.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| EZB | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -11.1% | -3.1% | -3.5% |
| 1Y | -66.1% | 37.0% | 13.6% |
Return vs Industry: EZB underperformed the German Healthcare industry which returned 37% over the past year.
Return vs Market: EZB underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| EZB volatility | |
|---|---|
| EZB Average Weekly Movement | 11.8% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: EZB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EZB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 131 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
Enzo Biochem, Inc. Fundamentals Summary
| EZB fundamental statistics | |
|---|---|
| Market cap | €22.13m |
| Earnings (TTM) | -€6.63m |
| Revenue (TTM) | €27.86m |
0.9x
P/S Ratio-3.6x
P/E RatioIs EZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZB income statement (TTM) | |
|---|---|
| Revenue | US$30.31m |
| Cost of Revenue | US$16.86m |
| Gross Profit | US$13.46m |
| Other Expenses | US$20.67m |
| Earnings | -US$7.21m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 44.39% |
| Net Profit Margin | -23.79% |
| Debt/Equity Ratio | 0.5% |
How did EZB perform over the long term?
See historical performance and comparisonDividends
20.1%
Current Dividend Yield-71%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 23:50 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enzo Biochem, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Berning | Craig-Hallum Capital Group LLC |
| Reni Benjamin | Rodman & Renshaw, LLC |
| Jack Wallace | Sidoti & Company, LLC |